RxDoctor Payments DataLook up a doctor →

Irina Milgram, PA

Medical · East Brunswick, NJNPI 1285823559

Payments from drug & device makers

$7,377in general payments, 2019–2025

Across 493 payments — averaging $14.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Dermavant Sciences, Inc.$687
  • Incyte Corporation$640
  • AbbVie$582
  • Johnson & Johnson$560
  • LEO Pharma Inc.$454
  • Mayne Pharma Commercial LLC$437
  • plus $4K from 27 others

What the payments were for

  • Food & beverage$7,17397%
  • Education$2033%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,377 in reported general payments places this provider in the 90th percentile of 573 medical providers in New Jersey.

See all medical providers in New Jersey

Medicare billing

Part B allowed, 2024
$177,906
Medicare patients
688
Services billed
4,303

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OtezlaApremilast14$66,704
Tacrolimus56$6,603
Gentamicin Sulfate135$5,482
Clobetasol Propionate79$4,242
CiclopiroxCiclopirox Olamine206$4,169
Betamethasone Diprop AugmentedBetamethasone/Propylene Glyc82$3,566
Fluocinonide75$3,426
Ciclopirox64$1,970
Ketoconazole113$1,845
Triamcinolone Acetonide118$1,772
Clindamycin Phosphate41$1,750
Metronidazole36$1,442
Betamethasone Valerate21$1,436
Betamethasone Dipropionate25$1,274
Econazole Nitrate32$1,126

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenOtezla$280$66,70414 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 573 medical providers in New Jersey.

Other medical in East Brunswick

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →